Basics of Chimeric Antigen Receptor (CAR) Immunotherapy
- 1st Edition - July 19, 2019
- Imprint: Academic Press
- Author: Mumtaz Y. Balkhi
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 1 9 5 7 3 - 4
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 9 7 4 7 - 9
Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteBasics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs and CAR-Therapy that has seen unprecedented interest in the immunotherapy field.
- Presents the first book to provide a basic understanding of chimeric antigen receptor (CARs) design, production and clinical application protocols
- Provides unique authority as the editor has worked directly with CARs
- Discusses the challenges encountered in actual clinical trials and how these challenges can be overcome
- Includes a full chapter on various challenges researchers should expect to encounter in the CAR-therapy field
Academia (research and development) who work on immunotherapies, (post) graduate students in biomedical science, researchers, scientists, (post) graduate students in translational medicine
- Edition: 1
- Published: July 19, 2019
- No. of pages (Paperback): 92
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780128195734
- eBook ISBN: 9780128197479
MB
Mumtaz Y. Balkhi
Dr. Mumtaz Balkhi brings dual backgrounds in cancer biology and immunotherapeutics to a research program in translational research. With a Ph.D. in Human Biology, he applies molecular biology techniques and utilizes his knowledge of molecular and cellular immunology to develop new gene therapies to improve immunotherapies against cancer. He has more than 20 publications in highly reputable journals including Science and Cell Press Journals. His 2013 publication in Science Signaling Journal featured as Cover Story and his latest publication in Cell Press journal was recently highlighted in Cell Press Crosstalk. Dr. Balkhi hopes to establish a Chimeric Antigen Receptor (CAR) Immunotherapy program. He is trained in this field and had an opportunity to drive and lead projects related to CAR Immunotherapy.
Affiliations and expertise
Professor, Chief Scientific Officer, Immunotherapeutic Lab (ITL)Read Basics of Chimeric Antigen Receptor (CAR) Immunotherapy on ScienceDirect